株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

内分泌療法薬の世界市場:2020年~2024年

Endocrinology Drugs Market by Therapy Area and Geography - Forecast and Analysis 2020-2024

発行 TechNavio (Infiniti Research Ltd.) 商品コード 356778
出版日 ページ情報 英文 120 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.91円で換算しております。
Back to Top
内分泌療法薬の世界市場:2020年~2024年 Endocrinology Drugs Market by Therapy Area and Geography - Forecast and Analysis 2020-2024
出版日: 2020年02月05日 ページ情報: 英文 120 Pages
概要

世界の内分泌療法薬市場は、2020年から2024年の予測期間中に7%のCAGRで成長し、247億8,000万米ドルの規模に達する見込みです。同市場は、内分泌障害の発生率の増加が成長要因の一つになっています。さらに、肥満と内分泌障害の関連性が、市場成長を促進すると予想されています。

当レポートでは、世界の内分泌療法薬市場について調査分析し、市場規模および成長率、市場動向、市場促進要因、課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の状況

  • 市場エコシステム

第3章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模(2019年)
  • 市場の見通し:2019-2024年の予測

第4章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • ライバルの脅威
  • 市況

第5章 市場セグメンテーション:治療分野別

  • 糖尿病治療薬-市場規模と予測2019-2024
  • hGH-市場規模と予測2019-2024
  • 甲状腺ホルモン障害-市場規模と予測2019-2024
  • テストステロン補充療法-市場規模と予測2019-2024
  • その他-市場規模と予測2019-2024

第6章 顧客の状況

第7章 地域別情勢

  • 地域別セグメンテーション
  • 北米-市場規模と予測2019-2024
  • 欧州-市場規模と予測2019-2024
  • アジア-市場規模と予測2019-2024
  • その他の地域-市場規模と予測2019-2024
  • 主要国
  • 市場機会:地域別

第8章 成長要因、課題、および動向

  • 市場成長要因
  • 市場の課題
  • 市場動向

第9章 ベンダーの展望

  • 概要
  • ベンダー情勢
  • 情勢の革新

第10章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Groupe Sanofi
  • Merck & Co. Inc.
  • Novartis International AG
  • Novo Nordisk AS
  • Pfizer Inc

第11章 付録

  • 調査範囲
  • 米ドルの通貨換算レート
  • 調査方法
  • 略語のリスト
目次
Product Code: IRTNTR40785

Technavio has been monitoring the global endocrinology drugs market and it is poised to grow by USD 24.78 bn during 2020-2024, progressing at a CAGR of 7% during the forecast period. Our reports on global endocrinology drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increase in incidence of endocrine disorders . In addition, association between obesity and endocrine disorders is anticipated to boost the growth of the global endocrinology drugs market as well.

Market Segmentation

Technavio's global endocrinology drugs market is segmented as below:

Therapy area

  • Diabetes Drugs
  • Thyroid Hormone Disorder Drugs
  • HGH
  • Testosterone Replacement Therapy
  • Others

Geographic segmentation

  • North America
  • Europe
  • Asia
  • ROW

Key Trends for global endocrinology drugs market growth

This study identifies association between obesity and endocrine disorders as the prime reasons driving the global endocrinology drugs market growth during the next few years.

Prominent vendors in global endocrinology drugs market

We provide a detailed analysis of around 25 vendors operating in the global endocrinology drugs market, including some of the vendors such as Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Eli Lilly and Co., GlaxoSmithKline Plc, Groupe Sanofi, Merck & Co. Inc., Novartis International AG, Novo Nordisk AS and Pfizer Inc. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Other 1

  • Market segments
  • Comparison by Other1 placement
  • Diabetes drugs - Market size and forecast 2019-2024
  • hGH - Market size and forecast 2019-2024
  • Thyroid hormone disorders - Market size and forecast 2019-2024
  • Testosterone replacement therapy - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Other1

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Groupe Sanofi
  • Merck & Co. Inc.
  • Novartis International AG
  • Novo Nordisk AS
  • Pfizer Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibits:

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 4
  • 5.Key Finding 5
  • 6.Key Finding 6
  • 7.Key Finding 7
  • 8.Market in focus
  • 9.Parent market
  • 10.Market characteristics
  • 11.Product / Service portfolio of key vendors included in the market definition
  • 12.Market segments
  • 13.Global - Market size and forecast 2019 - 2024 ($ billion)
  • 14.Global market: Year-over-year growth 2019 - 2024 (%)
  • 15.Five forces analysis 2019 & 2024
  • 16.Bargaining power of buyers
  • 17.Bargaining power of suppliers
  • 18.Threat of new entrants
  • 19.Threat of substitutes
  • 20.Threat of rivalry
  • 21.Market condition - Five forces 2019
  • 22.Other1 placement - Market share 2019-2024 (%)
  • 23.Comparison by Other1 placement
  • 24.Diabetes drugs - Market size and forecast 2019-2024 ($ billion)
  • 25.Diabetes drugs - Year-over-year growth 2019-2024 (%)
  • 26.hGH - Market size and forecast 2019-2024 ($ billion)
  • 27.hGH - Year-over-year growth 2019-2024 (%)
  • 28.Thyroid hormone disorders - Market size and forecast 2019-2024 ($ billion)
  • 29.Thyroid hormone disorders - Year-over-year growth 2019-2024 (%)
  • 30.Testosterone replacement therapy - Market size and forecast 2019-2024 ($ billion)
  • 31.Testosterone replacement therapy - Year-over-year growth 2019-2024 (%)
  • 32.Others - Market size and forecast 2019-2024 ($ billion)
  • 33.Others - Year-over-year growth 2019-2024 (%)
  • 34. Market opportunity by Other1
  • 35.Customer landscape
  • 36.Market share by geography 2019-2024 (%)
  • 37.Geographic comparison
  • 38.North America - Market size and forecast 2019-2024 ($ billion)
  • 39.North America - Year-over-year growth 2019-2024 (%)
  • 40.Europe - Market size and forecast 2019-2024 ($ billion)
  • 41.Europe - Year-over-year growth 2019-2024 (%)
  • 42.Asia - Market size and forecast 2019-2024 ($ billion)
  • 43.Asia - Year-over-year growth 2019-2024 (%)
  • 44.ROW - Market size and forecast 2019-2024 ($ billion)
  • 45.ROW - Year-over-year growth 2019-2024 (%)
  • 46.Key leading countries
  • 47.Market opportunity by geography ($ billion)
  • 48.Impact of drivers
  • 49.Impact of challenges
  • 50.Landscape disruption
  • 51.Industry risks
  • 52.Vendors covered
  • 53.Market positioning of vendors
  • 54.Abbott Laboratories - Overview (1/3)
  • 55.Abbott Laboratories - Overview (2/3)
  • 56.Abbott Laboratories - Overview (3/3)
  • 57.Abbott Laboratories - Business segments
  • 58.Abbott Laboratories - Key offerings
  • 59.Abbott Laboratories - Key customers
  • 60.Abbott Laboratories - Segment focus
  • 61.AbbVie Inc. - Overview (1/3)
  • 62.AbbVie Inc. - Overview (2/3)
  • 63.AbbVie Inc. - Overview (3/3)
  • 64.AbbVie Inc. - Business segments
  • 65.AbbVie Inc. - Key offerings
  • 66.AbbVie Inc. - Key customers
  • 67.AbbVie Inc. - Segment focus
  • 68.AstraZeneca Plc - Overview (1/3)
  • 69.AstraZeneca Plc - Overview (2/3)
  • 70.AstraZeneca Plc - Overview (3/3)
  • 71.AstraZeneca Plc - Product and service
  • 72.AstraZeneca Plc - Key offerings
  • 73.AstraZeneca Plc - Key customers
  • 74.AstraZeneca Plc - Segment focus
  • 75.Eli Lilly and Co. - Overview (1/3)
  • 76.Eli Lilly and Co. - Overview (2/3)
  • 77.Eli Lilly and Co. - Overview (3/3)
  • 78.Eli Lilly and Co. - Business segments
  • 79.Eli Lilly and Co. - Key offerings
  • 80.Eli Lilly and Co. - Key customers
  • 81.Eli Lilly and Co. - Segment focus
  • 82.GlaxoSmithKline Plc - Overview (1/3)
  • 83.GlaxoSmithKline Plc - Overview (2/3)
  • 84.GlaxoSmithKline Plc - Overview (3/3)
  • 85.GlaxoSmithKline Plc - Business segments
  • 86.GlaxoSmithKline Plc - Key offerings
  • 87.GlaxoSmithKline Plc - Key customers
  • 88.GlaxoSmithKline Plc - Segment focus
  • 89.Groupe Sanofi - Overview (1/3)
  • 90.Groupe Sanofi - Overview (2/3)
  • 91.Groupe Sanofi - Overview (3/3)
  • 92.Groupe Sanofi - Business segments
  • 93.Groupe Sanofi - Key offerings
  • 94.Groupe Sanofi - Key customers
  • 95.Groupe Sanofi - Segment focus
  • 96.Merck & Co. Inc. - Overview (1/3)
  • 97.Merck & Co. Inc. - Overview (2/3)
  • 98.Merck & Co. Inc. - Overview (3/3)
  • 99.Merck & Co. Inc. - Business segments
  • 100.Merck & Co. Inc. - Key offerings
  • 101.Merck & Co. Inc. - Key customers
  • 102.Merck & Co. Inc. - Segment focus
  • 103.Novartis International AG - Overview (1/3)
  • 104.Novartis International AG - Overview (2/3)
  • 105.Novartis International AG - Overview (3/3)
  • 106.Novartis International AG - Business segments
  • 107.Novartis International AG - Key offerings
  • 108.Novartis International AG - Key customers
  • 109.Novartis International AG - Segment focus
  • 110.Novo Nordisk AS - Overview (1/3)
  • 111.Novo Nordisk AS - Overview (2/3)
  • 112.Novo Nordisk AS - Overview (3/3)
  • 113.Novo Nordisk AS - Business segments
  • 114.Novo Nordisk AS - Key offerings
  • 115.Novo Nordisk AS - Key customers
  • 116.Novo Nordisk AS - Segment focus
  • 117.Pfizer Inc. - Overview (1/3)
  • 118.Pfizer Inc. - Overview (2/3)
  • 119.Pfizer Inc. - Overview (3/3)
  • 120.Pfizer Inc. - Business segments
  • 121.Pfizer Inc. - Key offerings
  • 122.Pfizer Inc. - Key customers
  • 123.Pfizer Inc. - Segment focus
  • 124.Currency conversion rates for US$
  • 125.Research Methodology
  • 126.Validation techniques employed for market sizing
  • 127.Information sources
  • 128.List of abbreviations
Back to Top